利弗利塞（Lifileucel）：FDA 批准的用于黑色素瘤的 T 细胞疗法。
Lifileucel: FDA-approved T-cell therapy for melanoma.
机构信息
Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, United States.
出版信息
Oncologist. 2024 Aug 5;29(8):648-650. doi: 10.1093/oncolo/oyae136.
Abstract
This commentary reports on the history of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy and where TIL fits into the treatment options for metastatic melanoma.
摘要
本述评报告了肿瘤浸润淋巴细胞（TIL）在过继细胞治疗中的历史，以及 TIL 在转移性黑色素瘤治疗选择中的地位。
相似文献
1
Lifileucel: FDA-approved T-cell therapy for melanoma.利弗利塞（Lifileucel）：FDA 批准的用于黑色素瘤的 T 细胞疗法。
Oncologist. 2024 Aug 5;29(8):648-650. doi: 10.1093/oncolo/oyae136.
2
Lifileucel: the first cellular therapy approved for solid tumours.利弗利塞细胞：首个获批用于实体瘤的细胞疗法。
Trends Cancer. 2024 Jun;10(6):475-477. doi: 10.1016/j.trecan.2024.04.003. Epub 2024 May 9.
3
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi).社论：首个自体肿瘤浸润淋巴细胞（TIL）过继细胞疗法监管批准 - Lifileucel（Amtagvi）。
Med Sci Monit. 2024 May 1;30:e944927. doi: 10.12659/MSM.944927.
4
Comment on "Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy" by Gustav J. Ullenhag et al.对古斯塔夫·J·乌伦哈格等人所著的《采用超声引导下经皮穿刺活检获取肿瘤浸润淋巴细胞对恶性黑色素瘤患者进行过继性T细胞治疗》的评论
Cancer Immunol Immunother. 2012 May;61(5):747; author reply 749. doi: 10.1007/s00262-012-1243-3. Epub 2012 Mar 20.
5
Lifileucel (Amtagvi): A cellular therapy for melanoma.利菲鲁塞（安塔格维）：一种用于黑色素瘤的细胞疗法。
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e77-e78. doi: 10.58347/tml.2024.1701h.
6
[Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].基于“肿瘤浸润淋巴细胞”的过继性细胞治疗原则
Rev Med Suisse. 2016 May 18;12(519):989-93.
7
[Future of malignant stage I melanoma. Immunology and immunotherapy].[恶性I期黑色素瘤的未来。免疫学与免疫治疗]
Ann Dermatol Venereol. 1995;122(5):324-35.
8
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.在免疫检查点抑制剂和靶向治疗进展后，晚期黑色素瘤患者单次自体肿瘤浸润淋巴细胞（TIL）细胞治疗 lifileucel 的疗效和安全性：C-144-01 研究连续队列的汇总分析。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005755.
9
Lifileucel: First Approval.利利昔单抗：首次批准。
Mol Diagn Ther. 2024 May;28(3):339-344. doi: 10.1007/s40291-024-00708-y. Epub 2024 Apr 16.
10
Tumor-infiltrating lymphocytes in melanoma.黑色素瘤中的肿瘤浸润淋巴细胞。
Curr Oncol Rep. 2012 Oct;14(5):468-74. doi: 10.1007/s11912-012-0257-5.
引用本文的文献
1
Immunotherapy in Melanoma.黑色素瘤的免疫疗法
Cancer Treat Res. 2025;129:173-186. doi: 10.1007/978-3-031-97242-3_9.
2
Tumor Microenvironment in Melanoma-Characteristic and Clinical Implications.黑色素瘤中的肿瘤微环境——特征与临床意义
Int J Mol Sci. 2025 Jul 15;26(14):6778. doi: 10.3390/ijms26146778.
3
From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors.从球体到类器官：实体瘤中CAR-T细胞疗法研究的下一代模型
Front Immunol. 2025 Jul 11;16:1626369. doi: 10.3389/fimmu.2025.1626369. eCollection 2025.
4
Engaging T cells for cleanup.激活T细胞进行清除。
Front Immunol. 2025 May 6;16:1551424. doi: 10.3389/fimmu.2025.1551424. eCollection 2025.
5
Harnessing Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Opportunities and Barriers to Clinical Integration.利用三阴性乳腺癌中的肿瘤浸润淋巴细胞：临床整合的机遇与障碍
Int J Mol Sci. 2025 May 1;26(9):4292. doi: 10.3390/ijms26094292.
6
Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors.拓展嵌合抗原受体T细胞和双特异性T细胞衔接器在实体瘤中的治疗范围
JCO Precis Oncol. 2025 Mar;9:e2400753. doi: 10.1200/PO-24-00753. Epub 2025 Mar 26.
7
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.肿瘤浸润淋巴细胞与溶瘤腺病毒TILT-123联合治疗转移性黑色素瘤的安全性和有效性
Cell Rep Med. 2025 Mar 18;6(3):102016. doi: 10.1016/j.xcrm.2025.102016.
8
Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Nursing Considerations.黑色素瘤的肿瘤浸润淋巴细胞疗法：护理考量
Clin J Oncol Nurs. 2025 Mar 14;29(2):125-129. doi: 10.1188/25.CJON.125-129.
9
Clinical Approaches for the Management of Skin Cancer: A Review of Current Progress in Diagnosis, Treatment, and Prognosis for Patients with Melanoma.皮肤癌管理的临床方法：黑色素瘤患者诊断、治疗及预后的当前进展综述
Cancers (Basel). 2025 Feb 19;17(4):707. doi: 10.3390/cancers17040707.
10
The Bidirectional Interplay between T Cell-Based Immunotherapies and the Tumor Microenvironment.基于T细胞的免疫疗法与肿瘤微环境之间的双向相互作用
Cancer Immunol Res. 2025 Apr 2;13(4):463-475. doi: 10.1158/2326-6066.CIR-24-0857.
本文引用的文献
1
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.在免疫检查点抑制剂和靶向治疗进展后，晚期黑色素瘤患者单次自体肿瘤浸润淋巴细胞（TIL）细胞治疗 lifileucel 的疗效和安全性：C-144-01 研究连续队列的汇总分析。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005755.
2
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.肿瘤浸润淋巴细胞治疗或伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233.
3
Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.既往治疗对转移性黑色素瘤患者肿瘤浸润淋巴细胞过继转移疗效的影响。
Clin Cancer Res. 2021 Oct 1;27(19):5289-5298. doi: 10.1158/1078-0432.CCR-21-1171.
4
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.随机 II 期试验：在转移性黑色素瘤患者中，采用淋巴细胞清除联合肿瘤浸润淋巴细胞过继转移治疗，联合或不联合树突状细胞疫苗接种。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002449.
5
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.免疫识别导致转移性乳腺癌完全持久消退的体细胞突变。
Nat Med. 2018 Jun;24(6):724-730. doi: 10.1038/s41591-018-0040-8. Epub 2018 Jun 4.
6
A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.维莫非尼与过继性细胞疗法联合治疗转移性黑色素瘤患者的一项试点试验。
Clin Cancer Res. 2017 Jan 15;23(2):351-362. doi: 10.1158/1078-0432.CCR-16-0906. Epub 2016 Oct 7.
7
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.转移性黑色素瘤患者肿瘤浸润淋巴细胞过继性转移前淋巴细胞清除强度的随机前瞻性评估
J Clin Oncol. 2016 Jul 10;34(20):2389-97. doi: 10.1200/JCO.2016.66.7220. Epub 2016 May 23.
8
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.基于突变特异性 CD4+T 细胞的癌症免疫疗法在一名上皮癌患者中的应用。
Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.
9
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.转移性黑色素瘤患者肿瘤浸润淋巴细胞的过继转移：既往免疫治疗失败后的意向治疗分析和疗效。
Clin Cancer Res. 2013 Sep 1;19(17):4792-800. doi: 10.1158/1078-0432.CCR-13-0380. Epub 2013 May 20.
10
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.从外显子组测序数据中挖掘被过继转移的肿瘤反应性 T 细胞识别的突变抗原。
Nat Med. 2013 Jun;19(6):747-52. doi: 10.1038/nm.3161. Epub 2013 May 5.
Zotero 插件